22 Mai 2018 Jahr - FDA convened a joint meeting of the Anesthetic
and Analgesic Drug Products Advisory Committee
and the Drug Safety and Risk Management
Advisory Committee to discuss the new drug
application for buprenorphine sublingual spray,
submitted by INSYS Development Company, Inc.,
for the treatment of moderate-to-severe acute
pain where the use of an opioid analgesic
isappropriate.
Zugefügt zum Band der Zeit:
Opioids and the FDA
Datum:
